CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW
24 sept. 2008 Voltfast®/Catafast® (50 mg diclofenac potassium) sachet a sugar- ... study comparing the bioavailability of diclofenac-K sachets (powder ...
s ClinPharmR
CATAFAST®/VOLTFAST® NOVARTIS PHARMA
Diclofenac potassium: powder for oral solution in sachets of 50 mg. Indications: Short-term treatment in the following acute condi- tions: post-traumatic pain
faf ae afe df a af a ?v=
Annex I List of the names pharmaceutical forms
https://ec.europa.eu/health/documents/community-register/2013/20130925126604/anx_126604_en.pdf
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights
Cardiovascular Risk. • Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events.
lbl
NOTICE : INFORMATION DE L'UTILISATEUR Cataflam 50 mg
Cataflam est utilisé pour le traitement symptomatique de courte durée (quelques jours) des affections suivantes : - Inflammation douloureuse et gonflement
Annex I List of the names pharmaceutical forms
https://www.ema.europa.eu/documents/referral/diclofenac-article-31-referral-annex-i_en.pdf
MEDICAL REVIEW(S)
27 oct. 2008 inflammatory drug (NSAID) 50 mg powder sachet for the acute treatment ... of powdered diclofenac-K similar to PRO-513
s MedR
Comparison of the Onset of Diclofenac Potassium Sachet(Voltfast
Potassium Sachet(Voltfast) and Enteric-. Coated Diclofenac Potassium(Cataflam) in Treatment of Pain Following Tooth. Extraction. Dirar A. Al-juma`a.
Summary of European Union decisions on marketing authorisations
25 oct. 2013 solution buvable en sachet-dose. 50 mg. Granules for oral solution. Oral use. EN25.10.2013 Official Journal of the European Union.
Summary of European Union decisions on marketing authorisations
25 oct. 2013 solution buvable en sachet-dose. 50 mg. Granules for oral solution. Oral use. EN25.10.2013 Official Journal of the European Union.